News
NGENF
5.37
-2.19%
-0.12
Weekly Report: what happened at NGENF last week (1229-0102)?
Weekly Report · 2d ago
Weekly Report: what happened at NGENF last week (1222-1226)?
Weekly Report · 12/29/2025 09:06
Weekly Report: what happened at NGENF last week (1215-1219)?
Weekly Report · 12/22/2025 09:06
NervGen Pharma Files SEC Registration to Advance Strategic Growth
TipRanks · 12/17/2025 22:13
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Newsfile · 12/17/2025 21:19
NERVGEN PHARMA CORP FILES FOR MIXED SHELF OF UP TO $150 MLN – SEC FILING
Reuters · 12/17/2025 21:03
Weekly Report: what happened at NGENF last week (1208-1212)?
Weekly Report · 12/15/2025 09:06
NervGen Pharma Proposes Amendment to Warrant Terms
TipRanks · 12/13/2025 01:07
NervGen Pharma Announces Proposed Amendment to Warrants
Newsfile · 12/13/2025 00:51
NERVGEN PHARMA CORP <NGEN.V>: RAYMOND JAMES RAISES TARGET PRICE TO C$8.00 FROM C$6.00
Reuters · 12/11/2025 12:36
CANADA RESEARCH ROUNDUP-BCE, Capital Power, Telus
Reuters · 12/11/2025 12:21
Weekly Report: what happened at NGENF last week (1201-1205)?
Weekly Report · 12/08/2025 09:06
Weekly Report: what happened at NGENF last week (1124-1128)?
Weekly Report · 12/01/2025 09:06
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment
TipRanks · 11/24/2025 12:44
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment
TipRanks · 11/24/2025 12:42
NervGen Pharma GAAP EPS of -$0.06
Seeking Alpha · 11/24/2025 12:22
NervGen Pharma Unveils Breakthrough Therapy Targeting Spinal Cord Injury Repair
Reuters · 11/24/2025 12:06
NervGen Pharma Corp. Raises US$10 Million in Private Placement
Reuters · 11/24/2025 12:05
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Newsfile · 11/24/2025 12:05
NervGen Pharma Reports NVG-291 Achieves Durable Functional Gains in Chronic Spinal Cord Injury Trial
Reuters · 11/24/2025 12:02
More
Webull provides a variety of real-time NGENF stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGENF
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.